ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MDWD / dividends
NAGE (57) GLAS (18) ACB (54) USNA (50) ⌘ Pro Terminal →

MediWound Ltd. (MDWD) Dividend Safety Gauge & 10-Year DRIP Compounder

$13.50 +1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.51

MediWound Ltd. (MDWD) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $171.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDWD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.50 (+1.50% 1D, market cap $171.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MDWD ranks #291 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MDWD compare to NAGE and GLAS in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $184.4M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $191.8M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDWD?
▼

For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #291 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.51 (+0.08%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (6)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$21 Bull$13 Base$10 Bear
📬 FREE MDWD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDWD)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY MDWD SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$12.22-1% Next Q
Q2 (-2Q)
43
Grade D$12.10+3.7% Next Q
Q3 (-1Q)
45
Grade D$12.55+7.6% Next Q
Current
48
Grade D$13.50-5.6% Hist 90D α
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MDWD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MDWD currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.08) and Max Pain ($14.18) forces dealer call-delta covering toward $20.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDWD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MDWD Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDWD)

  • ✓Walkthrough of MDWD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MDWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.78%⚡ TESTING RESISTANCE
2026-11-03O $13.86H $13.86L $13.30C $13.50VOL 110.1K
RES: $13.94SUP: $11.69SMA50: $13.08SMA200: $15.20
$18.24$16.50$14.75$13.00$11.26RES $13.94SUP $11.69$13.502026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDWD Butterfly Map → + Track MDWD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MDWD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDWD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MDWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDWD)

Health Care Rank #291 of 1015 ⚔️ NAGE vs MDWD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDWD vs. NAGE, GLAS, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MediWound Ltd. (MDWD) ranks #291 by composite RQD confidence (48/100, grade D) and #590 by equity capitalization ($171.7M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with MDWD at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MDWD ACTIVE
MediWound Ltd.
D 48/100 — — — +1.50% $171.7M Benchmark Subject
NAGE
Niagen Bioscience Inc.
D+ 57/100 11.4x 64.3% 16.8% +3.00% $184.4M /nage-vs-mdwd →
GLAS
Glass House Brands Inc. Subordinate Voting Shares
E 18/100 — 42.3% -9.2% +8.26% $191.8M /glas-vs-mdwd →
ACB
Aurora Cannabis Inc.
D+ 54/100 — — — +3.94% $251.5M /acb-vs-mdwd →
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% +2.87% $264.4M /usna-vs-mdwd →

2. MDWD Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

MediWound Ltd. (MDWD) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $171.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MDWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.50 (+1.50% 1D, market cap $171.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MDWD ranks #291 in composite RQD confidence.

How does MDWD compare to NAGE and GLAS in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $184.4M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $191.8M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDWD?

For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #291 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDWD trading relative to its 50-day, 200-day, and 52-week technical levels?

MDWD last traded at $13.50 (+1.50% on volume of 120,425 shares), positioning the stock +3.21% above its 50-day simple moving average ($13.08) and -11.18% below its 200-day simple moving average ($15.20). Across its 52-week range of $11.80 to $19.70, MDWD sits at the 21.5% percentile with a 14-day RSI of 53.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($12.24 to $14.76).

Direct Sub-Reports: MDWD RQD Cockpit MDWD 12M Forecast MDWD Earnings & Move MDWD Dividends & DRIP MDWD Insiders & 13F MDWD Whale Options MDWD Profit Sankey MDWD News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

MDWD — MediWound Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

MediWound Ltd. (MDWD) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.50 (+1.50% 1D, market capitalization $171.7M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MediWound Ltd. (MDWD) is a NASDAQ-listed issuer in the Health Care sector, classified under the Medicinal Chemicals and Botanical Products industry,..2B. — describes its specific products, customers, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $11.80 – $19.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped dependencies means ripple effects from suppliers, customers, or peers cannot be assessed from this dataset.

  • Key Question #1: Can MDWD sustain or expand its — operating margin and — ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $19.70 52-week high?
  • Key Question #3: How sensitive is MDWD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MDWD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MediWound Ltd. (MDWD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MDWD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDWD Bull vs. Bear Conversation Board — What's Your Call at $13.50?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDWD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MDWD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $16.49 (+24.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20) with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 is the strongest component of the rat

Here is why I am bullish on MDWD here at $13.30: The Forensic Balance Sheet pillar (13/20) with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 is the strongest component of the rating.. Compare MDWD's 0.0% operating margin and 0.0% ROIC against the rest of Medicinal Chemicals and Botanical Products. As long as cash conversion holds up, dips toward $12.63 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — MDWD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $10.37 (-22.0%)
Spot @ $13.30

The RQD rating shows 0% ROIC and 0% FCF yield, with Fundamental Cash Engine at 12/20 and Macro Regime Fit at 8/20.

I respect the product at MediWound Ltd., but the stock at $13.30 is a different story. The RQD rating shows 0% ROIC and 0% FCF yield, with Fundamental Cash Engine at 12/20 and Macro Regime Fit at 8/20.. FCF yield is 0.0% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%